High-activity Blood Coagulation Factor XI Mutant Ala570Thr Patent

Tue, 21 Apr 2026 10:47:50 +0000
Intellectual Property

The USPTO granted patent US12605430B2 to Ruijin Hospital Shanghai Jiaotong University School of Medicine for a high-activity blood coagulation factor XI mutant (Ala570Thr/A570T). The mutant demonstrates resistance to physiological inhibitors after activation and exhibits strong blood coagulation activity. The patent covers nucleotide sequences (SEQ ID NOs: 1-4), amino acid sequence (SEQ ID NO: 5), and applications for treating hemorrhagic diseases through gene therapy, gene editing, and recombinant protein replacement treatments.